Randox Covid-19 PCR Tests Reduced to £60 for Overseas Travel
Tuesday 13th April 2021
Randox Covid-19 PCR Tests Reduced to £60 for Overseas Travel
Randox, the UK’s largest Covid-19 PCR testing provider, today announced their support for UK holidaymakers seeking trips overseas by reducing the cost of PCR tests to support travel to £60 per test. Currently PCR tests can cost from £100 each, and often much more.
This announcement comes hot on the heels of the Department for Transport’s plans to open-up overseas travel, potentially from as early as 17th May, but dependent on PCR testing pre-departure and on return. Specific PCR testing requirements will be based on the grading of destination countries within a green, amber and red traffic light system.
Last week UK transport secretary Grant Shapps sought to lower the cost of coronavirus testing to help encourage foreign holidays this summer – and Randox have led the response.
Dr Peter FitzGerald, Randox Managing Director said;
“In recognition of the needs of both the travel industry and the British public at this unprecedented time, Randox will reduce the all-inclusive cost of PCR testing for those in the UK undertaking international travel to £60 per test. We can see the pressures faced by the both the travel industry and the general public and are committed to effective and economical testing to support holidaymakers and those undertaking international travel.
The £60 PCR test is based on a testing kit ordered, on-line, for home sample collection with the sample returned to the laboratory for testing. The cost is inclusive of VAT and logistics. In order to achieve the £60 price, which is limited to those undertaking international travel, purchasers will need to apply a discount code which can initially be obtained from airlines when booking travel.
Those passengers wishing to order a Randox PCR COVID-19 home test should visit: https://www.randoxhealth.com/covid-19-home-testing-kit/
Randox have been active in Covid-19 testing since early 2020, and currently have the largest Covid-19 testing network within the UK.
The Department of Transport report, produced by the Global Travel Taskforce and released on 9th April, shows how international travel could resume from 17 May 2021 at the earliest, in an accessible and affordable way. This includes the removal of the permission to travel form – meaning passengers would no longer need to prove they have a valid reason to leave the country.
The UK is a global leader in genome sequencing, which in positive cases allows the identification of variants of concern.
The risks posed by these variants remain significant, and restrictions for inbound passengers, such as 10-day managed quarantine, home quarantine, and stringent testing will remain in place – but will apply to people differently depending on whether the destination visited is categorised as ‘green’, ‘amber’ or ‘red’.
Green: arrivals will need to take a pre-departure test as well as a polymerase chain reaction (PCR) test on or before day 2 of their arrival back into the UK – but will not need to quarantine on return (unless they receive a positive result) or take any additional tests, halving the cost of tests on their return from holiday
Amber: arrivals will need to quarantine for a period of 10 days and take a pre-departure test, and a PCR test on day 2 and day 8 with the option for Test to Release on day 5 to end self-isolation early
Red: arrivals will be subject to restrictions currently in place for ‘red list’ countries which include a 10-day stay in a managed quarantine hotel, pre-departure testing and PCR testing on day 2 and 8
Testing remains an essential part of protecting public health as restrictions begin to ease – with all arrivals who are not exempt required to book a pre-departure, day 2 and day 8 test before travelling.
For further information on our £60 PCR test please contact the Randox Covid Customer Support team on email@example.com or 0800 2545 201.
For press enquiries please contact Amy Millar in the Randox PR team on firstname.lastname@example.org or 028 9442 2413
Randox in the media
COVID-19 | qPCR Assay
Detecting SARS-CoV-2 (COVID-19)
Accurate PCR Detection of SARS-CoV-2
Randox Laboratories have recently developed a COVID-19 qPCR assay, which can be used for the detection of nucleic acid from SARS-CovV-2 (ORF1ab) and Severe Acute Respiratory Syndrome ((SARS)/SARS-like) viruses (E-gene). PCR based assays are recommended to include two tests. One to detect a universal SARS-like gene and a secondary confirmatory test for gene sequences exclusive to SARS-CoV-2.
In a multiplex format, the Randox qPCR assay allows for differentiation of SARS-CoV-2 and SARS-like corona infections from other seasonal respiratory illnesses caused by viruses to prevent rapid spread of infection through the isolation of positive cases.
Our assay is compatible with sample matrices including nasal / throat swabs. This test is intended for use in the clinical setting as an aid in the screening and isolation of individuals that require quarantine and immediate intervention.
Internal control provided to monitor assay/sample integrity through the extraction and PCR process.
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Viral Respiratory Infection Array
SARS-CoV-2 Rapid Test
Vivalytic Test Menu
COVID-19 Testing: PCR (Diagnostic) vs Antibody
The advice from the World Health Organisation in relation to the COVID-19 pandemic has been simple; Test. Test. Test.
But what are the different types of COVID-19 tests and what are they used for?
Diagnostic (PCR) Testing
This type of testing detects SARS-CoV-2 (the virus that causes COVID-19) within the body and will tell you if you currently have COVID-19. PCR tests cannot tell you if you have had past infection.
Sample collection for a PCR test can vary, though it is usually in the form of a swab, which will gather an individual’s nasopharyngeal (nose and throat) secretions.
PCR tests for COVID-19 all use methods that detect a specific part of the viral genome – for example Viral RNA or Antigen.
A sample is prepared by extracting the chosen section of the genome, and then PCR (Polyamerase Chain Reaction) techniques are used to amplify (replicate) the genome section, ready for detection.
Viral RNA Tests
This type of test detects the RNA (Ribonucleic acid) contained within the SARS-CoV-2 virus.
It is this type of test, for RNA, that is recommended by The World Health Organisation for COVID-19 diagnosis.
Antigens are molecular structures on the surface of viruses that are recognized by the immune system and are capable of triggering an immune response.
Antigen tests detect the presence of the SARS-CoV-2 virus by looking for the antigen on the surface of the virus.
Randox COVID-19 Test
The Randox COVID-19 test, as recommended by the World Health Organisation, detects the RNA contained within the SARS-CoV-2 virus.
After sample extraction and amplification, the virus is detected on our patented Randox Biochip Technology platform.
The Randox Biochip, which can run multiple tests simultaneously, performs two tests for COVID-19 – one specific and one confirmatory – as recommended by the WHO. This delivers extra assurance of the correct diagnosis and avoids the need to repeat the test.
Antibody (Serology) Tests
Antibody (also known as serology) tests, are usually performed on a patient blood sample, and look for antibodies (a type of protein) that may have been developed by the patient’s immune system to fight off disease.
If present, antibodies may provide a degree of immunity for the patient against COVID-19 in the future.
However, there is still much unknown about the body’s antibody response to COVID-19, including;
- Whether all patients who have been infected with SARS-CoV-2 will generate antibodies (recent studies and news reports indicate that this isn’t the case. Click here for an example.)
- Whether those who have had more severe symptoms as a result of COVID-19 will produce more antibodies than those who had mild symptoms, or were asymptomatic.
- If antibodies from other coronaviruses previously experienced by the patient may be enough to fight off the virus, therefore eliminating the need for COVID-19 specific antibodies.
- How long any COVID-19 specific antibody response will last for.
- How much future immunity is provided by COVID-19 antibodies. Will it prevent the patient from being infected, or will future infection just be less severe?
If antibodies for the SARS-CoV-2 virus are present this can give an indication that the patient has been previously infected with COVID-19. Antibody tests do not confirm the real-time presence of the virus in your system.
For example, a negative antibody result does not necessarily mean the body has not been exposed to the SARS-CoV-2 virus. It could in fact, be currently infected, but has not yet generated antibodies. A diagnostic test will confirm current presence of the virus.
Therefore, it is recommended that antibody tests are used in tandem with a diagnostic test to determine a complete overview of the patient’s COVID-19 status.
Randox Health currently offers both diagnostic testing and antibody testing for SARS-CoV-2 (COVID-19).
A combination of diagnostic and antibody testing is available for individual purchase, or as part of our ‘Back to Business’ COVID-19 testing service, for staff screening.
Visit Randox Health to find out more.
Want to know more about Randox?
Contact us or visit our homepage to view more.